Carbon signs up Boston for injectable bulking agent
This article was originally published in Clinica
Executive Summary
Boston Scientific has gained US exclusive distribution rights to Carbon Medical Technologies' Durasphere injectable bulking agents for the treatment of stress urinary incontinence. In return, Boston has made an undisclosed equity investment in the private company. Boston also has the option to buy the technology.